POLBF - Poolbeg Pharma moving forward rapidly with POLB001
(NewsDirect)
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF)CEO Jeremy Skillington speaks to Thomas Warner from Proactive afterannouncing the pharma & biotech's interim results for the sixmonths to 30 June 2023. Skillington highlights Poolbeg's"healthy" financial position and attributes it to lowoperational cash burn and strong financial discipline. Skillingtonalso emphasises cost-effective R&D, citing examples like the LPSchallenge study and AI programs that utilise supercomputers forefficiency.
They continue to seeknon-diluted funding opportunities to support infectious diseaseprograms, following a €2.3 million grant from the Irish governmentin 2022 for an oral vaccine program. Operational achievements includepositive results from a POLB001 LPS human challenge trial, showingpotential in treating acute inflammatory conditions andoncology-related issues.
Thecompany's collaboration with CytoReason identified valuable drugtargets for influenza treatment. Additionally, progress was noted inoral vaccine delivery and clinical trials for an oral GLP-1 agonist.Skillington hinted at new indications for POLB001 in the oncologysector, addressing cytokine release syndrome, a significant marketopportunity. Future milestones include RSV dataset validation, oralvaccine encapsulation, and influenza drug target validation.
Thecompany remains focused on clinical trial preparations andpartnerships with pharmaceutical companies, reflecting a proactiveapproach to advancing their programs.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.